Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heart attack patients

Bristol-Myers Squibb (BMS) building

NICE ‘no’ for Opdivo in kidney cancer

BMS oncology drug knocked-back in draft guidance

- PMLiVE

LEO Pharma picks up AZ skin disease drugs in $1bn deal

Gains rights to eczema and psoriasis treatments

- PMLiVE

US cuts at Boehringer hit sales force hardest

And Arena Pharmaceuticals plans US and Swiss 'reductions'

- PMLiVE

NICE finally set to back wider use of Ferring’s Firmagon

And acknowledges drug's benefits for prostate cancer that spreads to the spine

- PMLiVE

Tracking comms trends: Europe in the global vanguard on value

From multi-disciplinary teamwork to pharma’s reputation, value and access to global briefs, our contributors tackle some of the key topics in communications today

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

- PMLiVE

Integrated thinking – it’s both art and science

Traditional disciplines, structures and processes are changing within the walls of pharmaceutical organisations

Celgene building

NICE rejects Celgene’s Vidaza for leukaemia

Final draft guidance cites ‘high degree of uncertainty’ over clinical efficacy

- PMLiVE

CDC says no to AZ’s intranasal flu vaccine FluMist

US government data reports “poor” efficacy for the injected vaccine alternative

National Institute for Health and Care Excellence NICE logo

NICE backs five new drugs after discounts agreed

Includes Novartis’ previously rejected lung cancer and melanoma therapies Zykadia and Mekinist

- PMLiVE

GSK’s triple COPD therapy tops Symbicort in phase III trial

Once-daily, single inhaler combination treatment showed “significant” improvement in lung function

- PMLiVE

SMC rejects Amgen’s Repatha over lack of outcomes data

But gives GlaxoSmithKline’s asthma drug Nucala the green light

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links